EUVIMEDDécouvrir EUVIMED
Crossref

Inhibition of the type 1 diabetes candidate gene PTPN2 aggravates TNF-α-induced human beta cell dysfunction and death

Arturo Roca-Rivada iD, Sandra Marín-Cañas iD, Maikel L Colli iD, Chiara Vinci iD, Toshiaki Sawatani iD, Lorella Marselli iD, Miriam Cnop iD, Piero Marchetti iD, Decio L Eizirik iD

Diabetologia · 2023

DOI: 10.1007/s00125-023-05908-5 ↗

At a glance

Journal article in Diabetologia, 2023. Written by Arturo Roca-Rivada and 8 co-authors. Institution: ULB Center for Diabetes Research, Medical Faculty, Université Libre De Bruxelles, Brussels, Belgium. arturo.roca.rivada@ulb.be. Major MEDLINE topics: Diabetes Mellitus, Type 1, Insulin-Secreting Cells. Cited 35 times so far (Crossref); 47 references. Funded by: NIDDK NIH HHS, European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie, INNODIA.

RésuméSubjectsRéférences bibliographiquesCiteRelated studies

Abstract (original language)

AIMS/HYPOTHESIS: TNF-α plays a role in pancreatic beta cell loss in type 1 diabetes mellitus. In clinical interventions, TNF-α inhibition preserves C-peptide levels in early type 1 diabetes. In this study we evaluated the crosstalk of TNF-α, as compared with type I IFNs, with the type 1 diabetes candidate gene PTPN2 (encoding protein tyrosine phosphatase non-receptor type 2 [PTPN2]) in human beta cells. METHODS: EndoC-βH1 cells, dispersed human pancreatic islets or induced pluripotent stem cell (iPSC)-derived islet-like cells were transfected with siRNAs targeting various genes (siCTRL, siPTPN2, siJNK1, siJNK3 or siBIM). Cells were treated for 48 h with IFN-α (2000 U/ml) or TNF-α (1000 U/ml). Cell death was evaluated using Hoechst 33342 and propidium iodide staining. mRNA levels were assessed by quantitative reverse transcription PCR (qRT-PCR) and protein expression by immunoblot. RESULTS: PTPN2 silencing sensitised beta cells to cytotoxicity induced by IFN-α and/or TNF-α by 20-50%, depending on the human cell model utilised; there was no potentiation between the cytokines. We silenced c-Jun N-terminal kinase (JNK)1 or Bcl-2-like protein 2 (BIM), and this abolished the proapoptotic effects of IFN-α, TNF-α or the combination of both after PTPN2 inhibition. We further observed that PTPN2 silencing increased TNF-α-induced JNK1 and BIM phosphorylation and that JNK3 is necessary for beta cell resistance to IFN-α cytotoxicity. CONCLUSIONS/INTERPRETATION: We show that the type 1 diabetes candidate gene PTPN2 is a key regulator of the deleterious effects of TNF-α in human beta cells. It is conceivable that people with type 1 diabetes carrying risk-associated PTPN2 polymorphisms may particularly benefit from therapies inhibiting TNF-α.

Subjects

MeSH terms (MEDLINE)

Diabetes Mellitus, Type 1Insulin-Secreting CellsHumansTumor Necrosis Factor-alphaProtein Tyrosine Phosphatase, Non-Receptor Type 2CytokinesCell DeathInterferon-alpha

Author keywords

Candidate geneCell deathPTPN2Pancreatic beta cellsPancreatic isletsTNF-αType 1 diabetes

Substances

Tumor Necrosis Factor-alphaProtein Tyrosine Phosphatase, Non-Receptor Type 2CytokinesInterferon-alphaPTPN2 protein, human

Authors and institutions

  • ULB Center for Diabetes Research, Medical Faculty, Université Libre De Bruxelles, Brussels, Belgium. arturo.roca.rivada@ulb.be.
  • ULB Center for Diabetes Research, Medical Faculty, Université Libre De Bruxelles, Brussels, Belgium.
  • Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Division of Endocrinology, Erasmus Hospital, Université Libre de Bruxelles, Brussels, Belgium.
  • WELBIO Department, WEL Research Institute, Wavre, Belgium.

ORCID profiles: Arturo Roca-Rivada, Sandra Marín-Cañas, Maikel L Colli, Chiara Vinci, Toshiaki Sawatani, Lorella Marselli, Miriam Cnop, Piero Marchetti, Decio L Eizirik

Funding

  • NIDDK NIH HHS
  • European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie
  • INNODIA
  • NIH grant
  • JDRF
  • INNODIA HARVEST
  • Walloon Region SPW-EER
  • Welbio-FNRS

Cite

APA

Roca-Rivada, A., Marín-Cañas, S., Colli, M. L., Vinci, C., Sawatani, T., Marselli, L., Cnop, M., Marchetti, P., & Eizirik, D. L. (2023). Inhibition of the type 1 diabetes candidate gene PTPN2 aggravates TNF-α-induced human beta cell dysfunction and death. Diabetologia. https://doi.org/10.1007/s00125-023-05908-5

Vancouver

Roca-Rivada A, Marín-Cañas S, Colli ML, Vinci C, Sawatani T, Marselli L, et al. Inhibition of the type 1 diabetes candidate gene PTPN2 aggravates TNF-α-induced human beta cell dysfunction and death. Diabetologia. 2023. doi:10.1007/s00125-023-05908-5

BibTeX
@article{RocaRivada2023,
  author = {Roca-Rivada, Arturo and Marín-Cañas, Sandra and Colli, Maikel L and Vinci, Chiara and Sawatani, Toshiaki and Marselli, Lorella and Cnop, Miriam and Marchetti, Piero and Eizirik, Decio L},
  title = {Inhibition of the type 1 diabetes candidate gene PTPN2 aggravates TNF-α-induced human beta cell dysfunction and death},
  journal = {Diabetologia},
  year = {2023},
  doi = {10.1007/s00125-023-05908-5}
}
Start for free →